drug
nitric oxide
Marketedupdated 5mo agoby $LIN LINDE PLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying nitric oxide
- —Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertension
- phase3NO During CPB in Neonates to Reduce Risk of AKI
- phase2Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis
- phase2Effect of iNO in Patients With Submassive and Massive PE
- N/AA Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
- phase2Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts
- phase3Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection
- phase2Diffuse Optical Monitoring With Inhaled Nitric Oxide
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 17, 2026
15 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (67)
- Jul 22, 2040method-of-use (U-3037)US 11672938
- Nov 3, 2036patentUS 9770570*PED
- May 3, 2036method-of-use (U-2148)US 9770570
- Feb 12, 2036formulationUS 10213572
- Oct 20, 2035formulationUS 10737051
- Aug 19, 2035patentUS 9279794*PED
- Feb 19, 2035formulationUS 9279794
- Jul 6, 2031patentUS 8291904*PED4.8y
- Jul 6, 2031patentUS 8291904*PED4.8y
- Jul 6, 2031patentUS 8573209*PED4.8y
- Jul 6, 2031patentUS 8573209*PED4.8y
- Jul 6, 2031patentUS 8573210*PED4.8y
- Jul 6, 2031patentUS 8573210*PED4.8y
- Jul 6, 2031patentUS 8776794*PED4.8y
- Jul 6, 2031patentUS 8776794*PED4.8y
- Jul 6, 2031patentUS 8776795*PED4.8y
- Jul 6, 2031patentUS 8776795*PED4.8y
- Jul 6, 2031patentUS 9265911*PED4.8y
- Jul 6, 2031patentUS 9295802*PED4.8y
- Jul 6, 2031patentUS 9408993*PED4.8y
- Jan 6, 2031formulationUS 82919044.3y
- Jan 6, 2031formulationUS 82919044.3y
- Jan 6, 2031formulationUS 85732094.3y
- Jan 6, 2031formulationUS 85732094.3y
- Jan 6, 2031formulationUS 85732104.3y
- Jan 6, 2031formulationUS 85732104.3y
- Jan 6, 2031formulationUS 87767944.3y
- Jan 6, 2031formulationUS 87767944.3y
- Jan 6, 2031formulationUS 87767954.3y
- Jan 6, 2031formulationUS 87767954.3y
- Jan 6, 2031formulationUS 92659114.3y
- Jan 6, 2031formulationUS 92958024.3y
- Jan 6, 2031formulationUS 94089934.3y
- Jul 14, 2030formulationUS 86077853.8y
- Jun 21, 2030formulationUS 111036693.7y
- Dec 30, 2029patentUS 11931377*PED3.2y
- Dec 30, 2029patentUS 8282966*PED3.2y
- Dec 30, 2029patentUS 8282966*PED3.2y
- Dec 30, 2029patentUS 8293284*PED3.2y
- Dec 30, 2029patentUS 8293284*PED3.2y
- Dec 30, 2029patentUS 8431163*PED3.2y
- Dec 30, 2029patentUS 8431163*PED3.2y
- Dec 30, 2029patentUS 8795741*PED3.2y
- Dec 30, 2029patentUS 8795741*PED3.2y
- Dec 30, 2029patentUS 8846112*PED3.2y
- Dec 30, 2029patentUS 8846112*PED3.2y
- Sep 21, 2029formulationUS 115112523.0y
- Aug 13, 2029formulationUS 109260542.9y
- Aug 13, 2029formulationUS 89440492.9y
- Aug 13, 2029method-of-use (U-2793)US 96040282.9y
- Jun 30, 2029compositionUS 119313772.7y
- Jun 30, 2029compositionUS 119313772.7y
- Jun 30, 2029method-of-use (U-1286)US 82829662.7y
- Jun 30, 2029method-of-use (U-1286)US 82829662.7y
- Jun 30, 2029method-of-use (U-1286)US 82932842.7y
- Jun 30, 2029method-of-use (U-1286)US 82932842.7y
- Jun 30, 2029method-of-use (U-1286)US 84311632.7y
- Jun 30, 2029method-of-use (U-1286)US 84311632.7y
- Jun 30, 2029method-of-use (U-1286)US 87957412.7y
- Jun 30, 2029method-of-use (U-1286)US 87957412.7y
- Jun 30, 2029method-of-use (U-1286)US 88461122.7y
- Jun 30, 2029method-of-use (U-1286)US 88461122.7y
- Jan 28, 2029formulationUS 97015382.3y
- Apr 21, 2027formulationUS 7560076201d
- Oct 17, 2026formulationUS 761859415d
- Oct 17, 2026method-of-use (U-3037)US 794722715d
- Jan 18, 2026method-of-use (U-3037)US 8057742
News(4)
- Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampedeEli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.fiercebiotech · 11d ago
- Nitric Oxide Delivery System Correction: NOxBOX Updates Use Instructions for NOxBOXi Nitric Oxide Delivery SystemThe NOxBOX NOxBOXi System may leak oxygen during inhaled nitric oxide therapyfda_medwatch · 14d ago
- Early Alert: Nitric Oxide Delivery System Issue from NOxBOXThe NOxBOX NOxBOXi System may leak oxygen during inhaled nitric oxide therapyfda_medwatch · 1mo ago
- The hidden history of BPC-157, a favorite MAHA peptideA compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.stat · 4mo ago
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that